Adj Barry Jacobson

Barry Jacobson is a South Africa–based clinician-scientist whose work bridges thrombosis, anticoagulation, and cardiovascular medicine. Affiliated with leading academic hospitals and research networks in Johannesburg, he has played a prominent role in advancing evidence-based care in settings with high burdens of infectious and non-communicable disease. His scholarship integrates clinical insight with translational and population-level research.

His research centres on venous thromboembolism, atrial fibrillation, prosthetic heart valves in pregnancy, and post-thrombotic syndrome, with major contributions to global registries such as GARFIELD-AF and GARFIELD-VTE. He has also led investigations into COVID-19–associated coagulopathy, vaccine safety, and thromboprophylaxis, as well as pharmacogenomics of warfarin dosing in African populations, highlighting precision medicine in underrepresented groups.

Additional strengths include point-of-care anticoagulation monitoring, aviation-related thrombosis, and inflammatory biomarkers in HIV. Across observational studies, randomized trial analyses, and meta-analyses, his work emphasizes pragmatic solutions for low- and middle-income contexts, multidisciplinary care, and improved risk stratification to enhance patient outcomes.